Pacific Biosciences Of California (PACB) Revenue Growth (5y) (2015 - 2026)
Pacific Biosciences Of California (PACB) Revenue Growth (5y) (2015 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.54 Bn | 176.25 Bn | 6.27 Bn |
| 2 | Stryker | 128.93 Bn | 126.05 Bn | 3.81 Bn |
| 3 | Medtronic | 108.84 Bn | 99.62 Bn | 6.41 Bn |
| 4 | Boston Scientific | 68.42 Bn | 66.96 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 47.32 Bn | 43.65 Bn | 1.29 Bn |
| 6 | GE HealthCare Technologies | 28.46 Bn | 26.18 Bn | 1.98 Bn |
| 7 | Dexcom | 28.46 Bn | 27.34 Bn | 750.30 Mn |
| 8 | Smith & Nephew | 26.97 Bn | 26.40 Bn | - |
| 9 | Koninklijke Philips | 25.55 Bn | 22.42 Bn | 2.07 Bn |
| 10 | Pacific Biosciences Of California | 420.50 Mn | 144.54 Mn | 12.84 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5.10% |
| Dec 31, 2025 | 10.47% |
| Sep 30, 2025 | 15.04% |
| Jun 30, 2025 | 18.42% |
| Mar 31, 2025 | 18.96% |
| Dec 31, 2024 | 7.03% |
| Sep 30, 2024 | 12.77% |
| Jun 30, 2024 | 7.90% |
| Mar 31, 2024 | 18.76% |
| Dec 31, 2023 | 24.48% |
| Sep 30, 2023 | 25.12% |
| Jun 30, 2023 | 17.13% |
| Mar 31, 2023 | 14.97% |
| Dec 31, 2022 | 1.87% |
| Sep 30, 2022 | 6.53% |
| Jun 30, 2022 | 12.06% |
| Mar 31, 2022 | 5.89% |
| Dec 31, 2021 | 6.97% |
| Jun 30, 2021 | 8.09% |
| Mar 31, 2021 | 8.68% |